Efficacy of Dexmedetomidine in Preventing Postoperative Delirium in Patients Undergoing Brain Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Maria Angélica Otero de Melo Dos Reis, Eloísa Bittencurt Thomaz de Assis, Harshada Kalaiarasan Swamy et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed perioperative dexmedetomidine for preventing postoperative delirium in adults undergoing brain surgery. It included five randomized controlled trials with 646 patients. Dexmedetomidine was associated with lower delirium risk than control (pooled risk ratio 0.47, 95% confidence interval 0.35-0.63; p < 0.00001), corresponding to a reported 53% reduction. Results were similar across brain tumor and other cranial procedures, with no statistical heterogeneity detected. Adverse events were comparable and generally mild; the authors call for further multicenter trials.
Key findings
- Across five randomized trials involving 646 patients, dexmedetomidine was associated with lower postoperative delirium risk (RR 0.47, 95% CI 0.35-0.63; p < 0.00001).
- The pooled estimate reflected a reported 53% reduction in delirium risk, with no statistical heterogeneity detected (I 2 = 0%).
- Subgroup estimates were similar for brain tumor and other cranial procedures; adverse events were comparable and generally mild.
Why it matters
Postoperative delirium is a concern in patients undergoing brain surgery. The pooled randomized-trial evidence suggests perioperative dexmedetomidine may reduce its occurrence, while reported adverse events were comparable and generally mild. The findings provide a focused estimate for neurosurgical patients, but confirmation in further multicenter trials is needed before the effect and optimal administration strategies are considered settled.
What to keep in mind
The evidence comes from five trials; the authors state that further multicenter trials are needed to confirm the findings and refine administration strategies.